James E. Foley

13.2k total citations · 2 hit papers
155 papers, 11.0k citations indexed

About

James E. Foley is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, James E. Foley has authored 155 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Endocrinology, Diabetes and Metabolism, 67 papers in Molecular Biology and 59 papers in Surgery. Recurrent topics in James E. Foley's work include Diabetes Treatment and Management (83 papers), Metabolism, Diabetes, and Cancer (55 papers) and Pancreatic function and diabetes (53 papers). James E. Foley is often cited by papers focused on Diabetes Treatment and Management (83 papers), Metabolism, Diabetes, and Cancer (55 papers) and Pancreatic function and diabetes (53 papers). James E. Foley collaborates with scholars based in United States, Switzerland and Sweden. James E. Foley's co-authors include Anja Schweizer, Bo Åhrén, Clifton Bogardus, Beth E. Dunning, S. Dejager, Stephen Lillioja, Éric Ravussin, P. Antonio Tataranni, Richard E. Pratley and A. Couturier and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

James E. Foley

152 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians

1993 1.2k citations James E. Foley, Éric Ravussin et al. profile →
Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance

2000 620 citations C. Weyer, James E. Foley et al. Diabetologia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James E. Foley United States	57	7.2k	4.3k	3.7k	2.6k	1.5k	155	11.0k
Lotte Bjerre Knudsen Denmark	50	7.1k 1.0×	4.4k 1.0×	3.6k 1.0×	1.5k 0.6×	742 0.5×	105	10.5k
Keith D. Kaufman United States	47	6.2k 0.9×	2.8k 0.7×	2.1k 0.6×	671 0.3×	915 0.6×	118	9.3k
Giorgio Sesti Italy	67	6.9k 1.0×	5.6k 1.3×	3.4k 0.9×	2.8k 1.1×	2.5k 1.7×	416	15.1k
Sunder Mudaliar United States	51	4.1k 0.6×	3.4k 0.8×	2.0k 0.5×	2.4k 0.9×	2.1k 1.5×	118	9.4k
Atsunori Kashiwagi Japan	55	3.5k 0.5×	4.2k 1.0×	2.2k 0.6×	2.1k 0.8×	1.8k 1.2×	231	11.3k
Juris J. Meier Germany	69	12.0k 1.7×	5.9k 1.4×	8.1k 2.2×	2.5k 1.0×	1.2k 0.8×	208	17.2k
Gary F. Lewis Canada	59	6.0k 0.8×	3.2k 0.7×	4.1k 1.1×	3.3k 1.3×	2.8k 1.9×	188	12.1k
Barry J. Goldstein United States	54	3.8k 0.5×	6.9k 1.6×	3.1k 0.8×	4.0k 1.5×	3.9k 2.7×	124	16.0k
Hiroshi Maegawa Japan	58	3.0k 0.4×	5.2k 1.2×	2.3k 0.6×	2.4k 0.9×	2.0k 1.3×	366	11.7k
Yoshimitsu Yamasaki Japan	63	4.1k 0.6×	3.3k 0.8×	4.0k 1.1×	1.7k 0.6×	1.4k 1.0×	191	11.2k

Countries citing papers authored by James E. Foley

Since Specialization

Citations

This map shows the geographic impact of James E. Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Foley more than expected).

Fields of papers citing papers by James E. Foley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Foley. The network helps show where James E. Foley may publish in the future.

Co-authorship network of co-authors of James E. Foley

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Foley. A scholar is included among the top collaborators of James E. Foley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Foley. James E. Foley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evans, Marc, Plamen Kozlovski, Päivi M. Paldánius, et al.. (2017). Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. Diabetes Therapy. 9(1). 27–36. 7 indexed citations

Kothny, Wolfgang, Valentina Lukashevich, James E. Foley, Marc Rendell, & Anja Schweizer. (2015). Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 58(9). 2020–2026. 24 indexed citations

Åhrén, Bo, Chantal Mathieu, Giovanni Bader, Anja Schweizer, & James E. Foley. (2014). Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 57(7). 1304–1307. 37 indexed citations

Schweizer, Anja, S. Dejager, James E. Foley, Q. Shao, & Wolfgang Kothny. (2010). Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obesity and Metabolism. 13(1). 55–64. 79 indexed citations

Foley, James E., et al.. (2009). Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes. Hormone and Metabolic Research. 41(12). 905–909. 87 indexed citations

Åhrén, Bo, Anja Schweizer, S. Dejager, et al.. (2008). Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes. Lund University Publications (Lund University). 6 indexed citations

Åhrén, Bo, et al.. (2008). Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes. Current Diabetes Reviews. 4(2). 129–145. 21 indexed citations

Vella, Adrian, Gerlies Bock, Paula D. Giesler, et al.. (2008). The effect of dipeptidyl peptidase‐4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double‐blind, placebo‐controlled crossover study. Clinical Endocrinology. 69(5). 737–744. 50 indexed citations

Azuma, Koichiro, Žofia Rádiková, Juliet Mancino, et al.. (2007). Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 93(2). 459–464. 98 indexed citations

10.

He, Yanling, et al.. (2006). Vildagliptin Does Not Affect C‐Peptide Clearance in Patients With Type 2 Diabetes. The Journal of Clinical Pharmacology. 47(1). 127–131. 5 indexed citations

11.

Mari, Andrea, William M. Sallas, Yanling He, et al.. (2005). Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 90(8). 4888–4894. 324 indexed citations

12.

Pratley, Richard E., James E. Foley, & Beth E. Dunning. (2001). Rapid Acting Insulinotropic Agents: Restoration of Early Insulin Secretion as a Physiologic Approach to Improve Glucose Control. Current Pharmaceutical Design. 7(14). 1375–1397. 30 indexed citations

13.

Weyer, C., James E. Foley, Clifton Bogardus, P. Antonio Tataranni, & Richard E. Pratley. (2000). Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia. 43(12). 1498–1506. 620 indexed citations breakdown →

14.

Paolisso, Giuseppe, et al.. (1995). A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 38(10). 1213–1217. 30 indexed citations

15.

Paolisso, Giuseppe, P. Antonio Tataranni, James E. Foley, et al.. (1995). A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia. 38(10). 1213–1217. 298 indexed citations

16.

Bell, Philip, Seung Hoon Cheon, James E. Foley, et al.. (1993). Design of novel agents for the therapy of non-insulin dependent diabetes mellitus (NIDDM). Bioorganic & Medicinal Chemistry Letters. 3(6). 1007–1012. 14 indexed citations

17.

Yki‐Järvinen, Hannele, Clifton Bogardus, & James E. Foley. (1990). Regulation of plasma lactate concentration in resting human subjects. Metabolism. 39(8). 859–864. 42 indexed citations

18.

Foley, James E.. (1988). Mechanisms of impaired insulin action in isolated adipocytes from obese and diabetic subjects. Diabetes/Metabolism Reviews. 4(5). 487–505. 20 indexed citations

19.

Foley, James E., et al.. (1985). Effect of puromycin on sugar transport in isolated rat adipocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 817(1). 187–189. 3 indexed citations

20.

Foley, James E., Rosemary Foley, & Jørgen Gliemann. (1980). Rate-limiting steps of 2-deoxyglucose uptake in rat adipocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 599(2). 689–698. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact